Apellis Pharmaceuticals Inc

NASDAQ:APLS   3:59:52 PM EDT
45.25
+0.06 (+0.13%)
Products

Apellis Reports Submission of NDA to FDA for Pegcetacoplan for Geographic Atrophy

Published: 06/01/2022 11:59 GMT
Apellis Pharmaceuticals Inc (APLS) - Apellis Announces Submission of New Drug Application to the FDA for Pegcetacoplan for Geographic Atrophy.
Apellis Pharmaceuticals Inc - FDA Decision on NDA Filing Acceptance is Expected in August 2022.
Apellis Pharmaceuticals Inc - Also Plans to Submit a Marketing Authorization Application to European Medicines Agency in Second Half of 2022.
Apellis Pharmaceuticals Inc - Pegcetacoplan Demonstrated a Favorable Safety Profile in All Three Studies.